Worth Watching: Eli Lilly and Co Just Reaches Yearly Low?

Worth Watching: Eli Lilly and Co Just Reaches Yearly Low?

The stock of Eli Lilly and Co (NYSE:LLY) hit a new 52-week low and has $62.31 target or 7.00% below today’s $67.00 share price. The 9 months bearish chart indicates high risk for the $73.34B company. The 1-year low was reported on Nov, 23 by Barchart.com. If the $62.31 price target is reached, the company will be worth $5.13B less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 17.13 million shares traded hands or 302.11% up from the average. Eli Lilly and Co (NYSE:LLY) has declined 1.78% since April 21, 2016 and is downtrending. It has underperformed by 7.11% the S&P500.

Analysts await Eli Lilly and Co (NYSE:LLY) to report earnings on January, 31 before the open. They expect $0.99 earnings per share, up 26.92% or $0.21 from last year’s $0.78 per share. LLY’s profit will be $1.08 billion for 16.92 P/E if the $0.99 EPS becomes a reality. After $0.88 actual earnings per share reported by Eli Lilly and Co for the previous quarter, Wall Street now forecasts 12.50% EPS growth.

Eli Lilly and Co (NYSE:LLY) Ratings Coverage

Out of 15 analysts covering Eli Lilly and Company (NYSE:LLY), 14 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 93% are positive. $125 is the highest target while $75 is the lowest. The $97.88 average target is 46.09% above today’s ($67) stock price. Eli Lilly and Company has been the topic of 40 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Jefferies on Friday, September 18. Berenberg initiated Eli Lilly and Co (NYSE:LLY) on Thursday, August 27 with “Buy” rating. The company was initiated on Wednesday, April 6 by Societe Generale. Credit Suisse upgraded the stock to “Outperform” rating in Tuesday, December 8 report. The stock has “Buy” rating given by Argus Research on Tuesday, August 2. The firm has “Outperform” rating by Leerink Swann given on Monday, December 28. The firm earned “Outperform” rating on Saturday, August 22 by Cowen & Co. Credit Suisse upgraded Eli Lilly and Co (NYSE:LLY) rating on Friday, October 9. Credit Suisse has “Outperform” rating and $105 price target. The firm earned “Buy” rating on Tuesday, September 27 by Goldman Sachs. The stock of Eli Lilly and Co (NYSE:LLY) has “Buy” rating given on Friday, September 18 by Bank of America.

According to Zacks Investment Research, “Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.”

Insitutional Activity: The institutional sentiment increased to 1.08 in Q2 2016. Its up 0.01, from 1.07 in 2016Q1. The ratio is positive, as 54 funds sold all Eli Lilly and Co shares owned while 365 reduced positions. 88 funds bought stakes while 362 increased positions. They now own 814.98 million shares or 2.31% less from 834.25 million shares in 2016Q1.
Burney holds 0.81% or 143,054 shares in its portfolio. Hallmark Management holds 0.19% or 15,490 shares in its portfolio. Dorsey Whitney Tru Limited Liability Corp has 21,749 shares for 0.39% of their US portfolio. First Interstate National Bank has 1,100 shares for 0.02% of their US portfolio. Hbk Sorce Advisory Lc owns 12,280 shares or 0.21% of their US portfolio. Moreover, Robeco Institutional Asset Bv has 0.66% invested in Eli Lilly and Co (NYSE:LLY) for 1.11M shares. Moreover, Aberdeen Asset Mgmt Public Ltd Com Uk has 0.07% invested in Eli Lilly and Co (NYSE:LLY) for 255,251 shares. Deutsche Bank & Trust Ag owns 3.35 million shares or 0.19% of their US portfolio. Ls Investment Advsrs Lc reported 35,142 shares or 0.19% of all its holdings. Ngam Advsr Limited Partnership has 0.09% invested in the company for 86,792 shares. Ntv Asset Mngmt Ltd Com has 1.82% invested in the company for 61,164 shares. Ancora Lc accumulated 4,890 shares or 0.04% of the stock. Arizona State Retirement Systems holds 0.45% of its portfolio in Eli Lilly and Co (NYSE:LLY) for 403,980 shares. The California-based Mechanics Bancorp Trust Department has invested 0.2% in Eli Lilly and Co (NYSE:LLY). California Public Employees Retirement System has 0.33% invested in the company for 2.57 million shares.

Insider Transactions: Since May 31, 2016, the stock had 1 buy, and 10 insider sales for $120.57 million net activity. 2,560 shares were bought by TAI JACKSON P, worth $205,875. $15.02M worth of Eli Lilly and Co (NYSE:LLY) shares were sold by LILLY ENDOWMENT INC. The insider Barnes Melissa S sold 992 shares worth $73,180. Zakrowski Donald A sold $100,873 worth of stock or 1,213 shares. Another trade for 2,248 shares valued at $182,927 was sold by Crowe Maria A.

More notable recent Eli Lilly and Co (NYSE:LLY) news were published by: Streetinsider.com which released: “Eli Lilly & Co. (LLY) Announces Solanezumab Phase 3 in Alzheimer’s Disease …” on November 23, 2016, also Reuters.com with their article: “BRIEF-Eli Lilly and CO incoming CEO David Ricks on CNBC – Amyloid Hypothesis …” published on November 23, 2016, Bloomberg.com published: “Eli Lilly’s Diabetes Misery Will Have Company” on October 26, 2016. More interesting news about Eli Lilly and Co (NYSE:LLY) were released by: Fool.com and their article: “Better Buy: Eli Lilly and Co vs. Pfizer” published on October 26, 2016 as well as Marketwatch.com‘s news article titled: “Eli Lilly falls, and hard, in race to Alzheimer’s treatment” with publication date: November 23, 2016.

LLY Company Profile

Eli Lilly and Company, incorporated on January 17, 1901, is engaged in drug manufacturing business. The Firm discovers, develops, makes and markets products in two divisions: human pharmaceutical products and animal health products. The Company’s products are sold in over 120 countries. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. The Company’s animal health business segment operates through the Company’s Elanco division, which develops, makes and markets products for both food animals and companion animals. The Firm makes and distributes its products through facilities in the United States, Puerto Rico and over 10 other countries.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment